2010-15-3

Basic information

• Product Name: PTH-GLYCINE
• Synonyms: 3-phenyl-2-thioguidanthion;3-phenyl-2-thio-hydantoi;glycine,3-phenyl-2-thiohydantoin;phenylthiohydantoin;3-PHENYL-2-THIOXOTETRAHYDRO-4H-IMIDAZOL-4-ONE;3-PHENYL-2-THIOHYDANTOIN;PTH-GLYCINE;PTH-DL-GLYCINE
• CAS NO: 2010-15-3
• Molecular Formula: C₉H₈N₂OS
• Molecular Weight: 192.24
• EINECS: 217-927-3
• Product Categories: Amino Acids;Amino Acids (N-Protected);Biochemistry;PTH-Amino Acids;Protein Sequencing;Protein Structural Analysis;Reagents for Protein Sequencing
• Mol File: 2010-15-3.mol
• Article Data: 30

Chemical Properties

• Melting Point: approximate 257℃
• Boiling Point: 292.1 °C at 760 mmHg
• Flash Point: 130.5 °C
• Appearance: /
• Density: 1.39 g/cm³
• Refractive Index: 1.684
• Storage Temp.: −20°C
• PKA: 11.13±0.20(Predicted)
• CAS DataBase Reference: PTH-GLYCINE(CAS DataBase Reference)
• NIST Chemistry Reference: PTH-GLYCINE(2010-15-3)
• EPA Substance Registry System: PTH-GLYCINE(2010-15-3)

Safety Data

• Hazard Codes: T
• Statements: 23/24/25
• Safety Statements: 36/37/39-45
• RIDADR: UN 2811 6.1/PG 3
• WGK Germany: 3
• RTECS: MU4025000
• HazardClass: 6.1(b)
• PackingGroup: III
• Hazardous Substances Data: 2010-15-3(Hazardous Substances Data)

Usage

General Description

PTH-Glycine, or parathyroid hormone-glycine, is a synthetic peptide analog of parathyroid hormone (PTH) that is used in the treatment of hypoparathyroidism. This condition is characterized by insufficient levels of PTH, leading to low calcium levels in the blood. PTH-Glycine works by mimicking the effects of natural PTH, stimulating the release of calcium from the bones, increasing calcium reabsorption in the kidneys, and promoting the production of active vitamin D, all of which help to raise blood calcium levels. This synthetic analog has a longer half-life than natural PTH, allowing for less frequent dosing and greater convenience for patients. PTH-Glycine is typically administered by injection and has been shown to effectively manage hypoparathyroidism and improve calcium levels in the bloodstream.

InChI:InChI=1/C9H8N2O2S/c12-8-6-11(9(13)10-8)14-7-4-2-1-3-5-7/h1-5H,6H2,(H,10,12,13)

Upstream product

• 103-72-0 phenyl isothiocyanate 
• 56-40-6 glycine 
• 143827-44-5 N-(cyano, carbethoxy-methyl) N'-phenyl thiouree 
• 24066-82-8 ethyl 2-isothiocyanatoacetate 
• 62-53-3 aniline 
• 79-04-9 chloroacetyl chloride 
• 103-85-5 monophenylthiourea 
• 123-91-1 1,4-dioxane 
• 4464-35-1 glycyl=>L-leucyl=>-L-leucine 
• 81511-63-9 2-(N-phenyl carboxamidomethyl thio)-5-phenyl-1,3,4-oxadiazole 
• 623-33-6 glycine ethyl ester hydrochloride 
• 2215-20-5 2-[(phenylcarbamothioyl)amino]acetic acid 
• 555-48-6 2-amino-N-phenyl-acetamide 
• 616-34-2 methoxycarbonylmethylamine 

Downstream Products

• 17583-69-6 1-benzoyl-3-phenyl-2-thioxo-imidazolidin-4-one 
• 61632-47-1 5-isopropylidene-3-phenyl-2-thioxo-imidazolidin-4-one 
• 53865-29-5 5-(2-nitro-benzylidene)-3-phenyl-2-thioxo-imidazolidin-4-one 
• 101821-95-8 2-amino-3,5-dihydro-3-phenyl-4H-imidazol-4-one 
• 87736-68-3 4-furfurylidene-1-phenyl-2-thioxoimidazolidin-5-one 
• 2221-13-8 3-phenylimidazolidine-2,4-dione 
• 479355-35-6 5-(bis-methylsulfanyl-methylene)-3-phenyl-2-thioxo-imidazolidin-4-one 
• 97724-61-3 2-phenyl-3-thioxo-2H-imidazo[1,5-b]isoquinoline-1,5-dione 
• 17452-09-4 2-mercapto-1-phenylimidazole 
• 53514-63-9 3-phenyl-1,3-dihydro-imidazo[4,5-b]quinoline-2-thione 

Relevant articles and documents

2-Polystyrylsulfonyl ethanol supports for the solid-phase syntheses of hydantoins and ureas

Reaction of sodium polystyrylsulfinate 1 with 2-chloroethanol gave the 2-arylsulfonyl ethanol resin 2, which was converted to the polymer-supported amine 5. Amine 5 was coupled with an isocyanate or an isothiocyanate to give the polymer-supported urea der

Identification of 2-thioxoimidazolidin-4-one derivatives as novel noncovalent proteasome and immunoproteasome inhibitors

This paper describes the design, synthesis, and biological evaluation of 2-thioxoimidazolidin-4-one derivatives as inhibitors of proteasome and immunoproteasome, potential targets for the treatment of hematological malignancies. In particular, we focused our efforts on the design of noncovalent inhibitors, which might be a promising therapeutic option potentially devoid of drawbacks and side-effects related to irreversible inhibition. Among all the synthesized compounds, we identified a panel of active inhibitors with Ki values towards one or two chymotrypsin-like activities of proteasome (β5c) and immunoproteasome (β5i and β1i subunits) in the low micromolar range. Docking studies suggested a unique binding mode of the molecules in the catalytic site of immunoproteasome proteolytic subunits.

Design and evaluation of non-carboxylate 5-arylidene-2-thioxo-4-imidazolidinones as novel non-competitive inhibitors of protein tyrosine phosphatase 1B

Protein tyrosine phosphatase 1B (PTP1B) acts as a negative regulator of insulin and leptin signalling and is crucially involved in the development of type 2 diabetes mellitus, obesity, cancer and neurodegenerative diseases. Pursuing our efforts to identify PTP1B inhibitors endowed with drug-like properties, we designed and evaluated 3-aryl-5-arylidene-2-thioxo-4-imidazolidinones (7) as a novel class of non-carboxylate PTP1B inhibitors. In agreement with our design, kinetic studies demonstrated that selected compounds 7 act as reversible, non-competitive inhibitors of the target enzyme at low micromolar concentrations. Accordingly, molecular docking experiments suggested that these inhibitors can fit an allosteric site of PTP1B that we previously individuated. Moreover, cellular assays demonstrated that compound 7e acts as a potent insulin-sensitizing agent in human liver HepG2 cells. Taken together, our results showed that these non-competitive PTP1B inhibitors can be considered promising lead compounds aimed to enhance druggability of the target enzyme and identify novel antidiabetic drugs.

Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds

Somatic mutations of isocitrate dehydrogenase 1 (IDH1) at R132 are frequently found in certain cancers such as glioma. With losing the activity of wild-type IDH1, the R132H and R132C mutant proteins can reduce α-ketoglutaric acid (α-KG) to d-2-hydroxyglutaric acid (D2HG). The resulting high concentration of D2HG inhibits many α-KG-dependent dioxygenases, including histone demethylases, to cause broad histone hypermethylation. These aberrant epigenetic changes are responsible for the initiation of these cancers. We report the synthesis, structure-activity relationships, enzyme kinetics, and binding thermodynamics of a novel series of 2-thiohydantoin and related compounds, among which several compounds are potent inhibitors of mutant IDH1 with Ki as low as 420 nM. X-ray crystal structures of IDH1(R132H) in complex with two inhibitors are reported, showing their inhibitor-protein interactions. These compounds can decrease the cellular concentration of D2HG, reduce the levels of histone methylation, and suppress the proliferation of stem-like cancer cells in BT142 glioma with IDH1 R132H mutation.